Catalog No.
DHB96801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-nd
Clonality
Monoclonal
Target
HLA class II histocompatibility antigen, DRB1 beta chain, Human leukocyte antigen DRB1, HLA-DRB1
Concentration
2.22 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01911
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Hu1D10, CAS: 267227-08-7
Clone ID
Apolizumab
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab), PMID: 11842393
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study, PMID: 17071489
A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia, PMID: 19860603
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab), PMID: 28140096
Novel therapies for chronic lymphocytic leukemia, PMID: 15010151
Targeting HLA-DR, PMID: 19886843
Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia, PMID: 18336199
Newer monoclonal antibodies for hematological malignancies, PMID: 18565392
Emerging drugs for chronic lymphocytic leukaemia, PMID: 16503834
Gateways to clinical trials, PMID: 12949633
Gateways to clinical trials, PMID: 14685303
Monoclonal antibody therapy of chronic lymphocytic leukemia, PMID: 12721266
Novel immune-based treatment strategies for chronic lymphocytic leukemia, PMID: 16155015
Hematologic malignancies: new developments and future treatments, PMID: 12170431
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells, PMID: 14630799
Monoclonal antibodies in the treatment of lymphoid leukemia, PMID: 12973402
CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells, PMID: 16109421
AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients, PMID: 12113055
Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro, PMID: 20171736
In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells, PMID: 12153000
Antibodies in the treatment of lymphoma, PMID: 16163182
Protein design labs begins Phase I trial of Remitogen in cancer patients with solid tumors, PMID: 12113045
For research use only. Not for human or drug use.
